
Doc T
655 posts

Doc T
@DoctorStock06
Equity/Real Estate Investor, Ph.D/Psychotherapist, Retired LEO, Expert Marksman, Lover of Nature/Carnivore/IF/Iced Americano w/Splash of Heavy Cream.



🧬 7 of 9 women with triple-negative breast cancer had their tumors essentially erased. Zero immune-related adverse events. Compare that to Keytruda + chemo: 65%, but with autoimmune side effects that can be permanent — thyroid damage, adrenal failure, lung & liver inflammation. That’s the result $NWBO in-licensed platform just produced. Today (4/29), Pawel Kalinski explained why. It’s not luck. It’s molecular design. Cold tumors fail immunotherapy because there are no T cells inside to release. The αDC1 platform builds the missing instructor cells in a lab — supercharged dendritic cells that pump out IL-12 (the “go kill” signal) at 100x normal, and train T cells carrying both an antigen receptor AND stress-sensors. They recognize cancer even when it hides its identity. They spare healthy cells. The companion CKM regimen does the same thing as a drug given IV. The key ingredient is $AIM Ampligen (rintatolimod) — a TLR3 agonist that hits the immune accelerator without hitting the inflammation switch. Standard poly-ICLC hits both. That’s why CKM works at full IV dose without the flu-like toxicity of other adjuvants. Bonus selectivity: tumors run elevated NF-kB. Healthy tissue doesn’t. CKM amplifies ONLY where cancer is. One catch — same-day dosing with checkpoint blockade is mandatory. 24h late = 20% gone. 5d late = no effect. Next-gen #DCVax-Direct integrates this on the #EDEN bioreactor. $NWBO controls the IP. Full transcript: investorshub.advfn.com/boards/read_ms…





















